Valneva (0OB3) (($FR:VLA)) has held its Q4 earnings call. Read on for the main highlights of the call. Valneva’s recent earnings call painted a ...

Analysts have recently evaluated Valneva and provided 12-month price targets. The average target is $17.5, accompanied by a ...

Valneva anticipates total product sales of €170 million to €180 million and total revenues of €180 million to €190 million for 2025, driven by increased IXCHIQ sales and growth in IXIARO and DUKORAL.

Met 2024 growth targets for product sales (+13% vs 2023) and total revenues (+10% vs 2023)Strong year-end cash position of €168.3 million including sale of Priority Review Voucher1, successful private ...

The global attenuated vaccines market is set for remarkable expansion, with sales projected to surge from USD 5,068.2 million in 2024 to an estimated USD 9,693.9 million by 2034. This growth ...

NEW YORK, March 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to ...

Pomerantz LLP is investigating claims on behalf of investors of  Valneva SE ("Valneva" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980 ...

the U.S. Centers for Disease Control and Prevention ("CDC") posted a notice on its website announcing that "CDC is currently investigating five hospitalizations for cardiac or neurologic events ...

Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; ...

If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older Saint Herblain (France), February 28, 2025 – ...